Dr. Kamala Maddali is a biotech, pharma, diagnostics and life sciences executive and board advisor with over 17 years of deep expertise in Precision Medicine implementing strategic initiatives across many Fortune 500 companies, most notably Merck and Co., Quintiles and Quest Diagnostics. She holds a Ph.D. in Pharmacology from the University of Missouri-Columbia and a doctorate in Veterinary Medicine from Tirupati, India. She currently is an executive advisor to companies focused in Precision Medicine, Artificial Intelligence and digital health companies in healthcare. Dr. Maddali won the 2016 Healthcare Heroes Finalist Award for “Innovation-Individual” category at NJBIZ. Dr. Maddali received many awards focused on “women empowerment in Healthcare” from several organizations in the USA. Dr. Maddali served as a Vice Chair for the Women in Bio (WIB) Philadelphia chapter. The Women In Bio organization promotes careers, leadership, and entrepreneurship for women in the life sciences. Dr. Maddali was invited in 2017 for the NYSE Closing bell ringing ceremony. Dr. Maddali was interviewed by CNBC in December 2018 on Precision Medicine advancements and Blockchain.
Professor, Internal Medicine and Computer Science; Hugh Kaul Endowed Chair, Personalized Medicine; Director, Hugh Kaul Precision Medicine Institute
Matt Might has been the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) since 2017. At UAB, Matt is the Hugh Kaul Endowed Chair of Personalized Medicine, a Professor of Internal Medicine and a Professor of Computer Science.
From 2016 to 2018, Matt was a Strategist in the Executive Office of the President in The White House. In 2015, Matt joined the faculty of the Department of Biomedical Informatics at the Harvard Medical School, first as Visiting Professor and since 2017 as Senior Lecturer.
Matt is co-founder and Chief Scientific Officer of NGLY1.org, and he was a co-founder and Scientific Advisor to Pairnomix. Q State Biosciences acquired Pairnomix in October 2018 and Matt remains a Scientific Advisor and Board Member.